{
    "eid": "2-s2.0-84977577189",
    "title": "Pharmacological and safety profile of dexlansoprazole: A new proton pump inhibitor - implications for treatment of gastroesophageal reflux disease in the Asia Pacific region",
    "cover-date": "2016-01-01",
    "subject-areas": [
        {
            "$": "Gastroenterology",
            "@code": "2715"
        },
        {
            "$": "Neurology (clinical)",
            "@code": "2728"
        }
    ],
    "keywords": [
        "Asia",
        "Delayed-action preparations",
        "Dexlansoprazole",
        "Gastroesophageal reflux",
        "Proton pump inhibitors"
    ],
    "authors": [
        "Khean Lee Goh"
    ],
    "citedby-count": 17,
    "ref-count": 51,
    "ref-list": [
        "Changing trends in gastrointestinal disease in the Asia-Pacific region",
        "Gastroesophageal reflux disease: An Asian perspective",
        "Epidemiology of gastroesophageal reflux disease in asia: A systematic review",
        "Gastroesophageal Reflux Disease in Asia: A historical perspective and present challenges",
        "Prevalence of gastrointestinal symptoms in a multiracial asian population, with particular reference to reflux-type symptoms",
        "Racial differences in the prevalence of heartburn [1]",
        "Health-related quality of life in patients with gastro-oesophageal reflux disease under routine care: 5-year follow-up results of the ProGERD study",
        "Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: Survey of a US cohort",
        "Unmet treatment needs of gastroesophageal reflux disease in Asia: Gastroesophageal reflux disease in Asia Pacific Survey",
        "Nocturnal gastroesophageal reflux disease: Issues, implications, and management strategies",
        "The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD",
        "Work productivity and activity impairment in gastroesophageal reflux disease in Korean full-time employees: A multicentre study",
        "Chronic gastrointestinal symptoms and quality of life in the Korean population",
        "Review article: The unmet needs in delayed-release proton-pump inhibitor therapy in 2005",
        "Review article: Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy",
        "Pilot Studies to Identify the Optimum Duration of Concomitant Helicobacter pylori Eradication Therapy in Thailand",
        "Lifestyle factors affecting gastroesophageal reflux disease symptoms: A cross-sectional study of healthy 19864 adults using FSSG scores",
        "GERD patient study: patients and their medications",
        "Dexlansoprazole MR for the management of gastroesophageal reflux disease",
        "Treatment patterns and symptom control in patients with GERD: US community based survey",
        "Systematic review: Persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies",
        "Nonerosive reflux disease",
        "Diagnostic value of the PPI test for detection of GERD in Korean patients and factors associated with PPI responsiveness",
        "Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers",
        "Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: A review of a special problem",
        "Recent safety concerns with proton pump inhibitors",
        "ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents",
        "Clopidogrel and proton pump inhibitors: Influence of pharmacological interactions on clinical outcomes and mechanistic explanations",
        "The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects",
        "The science of acid control-therapeutic implications: PPI metabolism",
        "Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC)",
        "FDA reminder to avoid concomitant use of Plavix (clopidogrel) and omeprazole",
        "Plavix (clopidogrel bisulfate) tablet",
        "Pharmacokinetic drug interaction profiles of proton pump inhibitors: An update",
        "Prescribing Information",
        "Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans",
        "Prescribing Information",
        "Clinical trial: The effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease",
        "Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: A combined analysis of randomized controlled clinical trials",
        "Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg",
        "Clinical trial: The effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor - Evidence for dosing flexibility",
        "The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: Evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor",
        "A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers",
        "Maintenance of Heartburn Relief After Step-Down From Twice-Daily Proton Pump Inhibitor to Once-Daily Dexlansoprazole Modified Release",
        "Textbook of gastroenterology",
        "Clinical trial: Dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis",
        "Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease",
        "Clinical trial: Efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - Maintenance of healing and symptom relief",
        "Effects of dexlansoprazole mr, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects",
        "Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: Global clinical trial experience",
        "Gastro-oesophageal reflux disease in Asia: Birth of a 'new' disease?"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Siriraj Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Seongnam",
            "affilname": "Seoul National University Bundang Hospital",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Manila",
            "affilname": "University of Santo Tomas Hospital",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Depok",
            "affilname": "Universitas Indonesia",
            "affiliation-country": "Indonesia"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "Chang Gung Memorial Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Seoul",
            "affilname": "Korea University College of Medicine",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Kuala Lumpur",
            "affilname": "Universiti Malaya",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Kaohsiung",
            "affilname": "Veterans General Hospital-Kaohsiung Taiwan",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Hong Kong",
            "affilname": "The University of Hong Kong",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "New Taipei City",
            "affilname": "Fu Jen Catholic University",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Bucheon-si",
            "affilname": "The Catholic University of Korea",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Hong Kong",
            "affilname": "Chinese University of Hong Kong",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Quezon City",
            "affilname": "St. Luke's College of Medicine-William H. Quasha Memorial",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Singapore City",
            "affilname": "Takeda Pharmaceuticals (Asia-Pacific) Pte. Ltd",
            "affiliation-country": "Singapore"
        }
    ],
    "funding": []
}